Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard?
Mené sur 770 patients atteints d'un adénocarcinome canalaire du pancréas de stade métastatique (durée médiane de suivi : 16,1 mois), cet essai randomisé international de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité d'une chimiothérapie de première ligne de type NALIRIFOX (irinotécan liposomal, oxaliplatine, leucovorine et fluorouracile) et d'une chimiothérapie combinant nab-paclitaxel et gemcitabine
Pancreatic ductal adenocarcinoma, with an annual number of deaths exceeding 530 000 patients, 1 undoubtedly requires new, potent treatment strategies. The Surveillance, Epidemiology, and End Results (SEER) programme demonstrated that in the period from 1977 to 2013, pancreatic ductal adenocarcinoma remained the cancer with the worst 5-year overall survival rate among all common cancers. In this 36-year period, the 5-year overall survival only improved from 2·5% to 8·7%, clearly less than for most other cancers.
The Lancet 2023